Does the media refer more to ACOG or CTNM?

In the previous week, Alpha Cognition had 2 more articles in the media than Contineum Therapeutics. MarketBeat recorded 3 mentions for Alpha Cognition and 1 mentions for Contineum Therapeutics. Alpha Cognition's average media sentiment score of 1.06 beat Contineum Therapeutics' score of 0.93 indicating that Alpha Cognition is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alpha Cognition 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Contineum Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate ACOG or ZSQR?

Alpha Cognition presently has a consensus price target of $14.67, suggesting a potential upside of 148.17%. Given Alpha Cognition's stronger consensus rating and higher possible upside, equities research analysts clearly believe Alpha Cognition is more favorable than Coeptis Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alpha Cognition 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer ACOG or ZSQR?

In the previous week, Alpha Cognition had 2 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 3 mentions for Alpha Cognition and 1 mentions for Coeptis Therapeutics. Alpha Cognition's average media sentiment score of 1.06 beat Coeptis Therapeutics' score of 0.94 indicating that Alpha Cognition is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alpha Cognition 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Coeptis Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ACOG or IMMX?

In the previous week, Alpha Cognition had 2 more articles in the media than Immix Biopharma. MarketBeat recorded 3 mentions for Alpha Cognition and 1 mentions for Immix Biopharma. Alpha Cognition's average media sentiment score of 1.06 beat Immix Biopharma's score of 0.93 indicating that Alpha Cognition is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alpha Cognition 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immix Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ACOG or STRO?

In the previous week, Alpha Cognition had 1 more articles in the media than Sutro Biopharma. MarketBeat recorded 3 mentions for Alpha Cognition and 2 mentions for Sutro Biopharma. Alpha Cognition's average media sentiment score of 1.06 beat Sutro Biopharma's score of 0.72 indicating that Alpha Cognition is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alpha Cognition 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sutro Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Alpha Cognition (ACOG) Competitors

$5.91 -0.17 (-2.80%)

Closing price 04:00 PM Eastern

Extended Trading

$6.00 +0.09 (+1.44%)

As of 04:10 PM Eastern

Compare

ACOG vs. AQST, CTNM, ZSQR, IMMX, and STRO

Should you buy Alpha Cognition stock or one of its competitors? MarketBeat compares Alpha Cognition with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Alpha Cognition include Aquestive Therapeutics (AQST), Contineum Therapeutics (CTNM), Coeptis Therapeutics (ZSQR), Immix Biopharma (IMMX), and Sutro Biopharma (STRO). These companies are all part of the "pharmaceutical products" industry.

How does Alpha Cognition compare to Aquestive Therapeutics?

Alpha Cognition (NASDAQ:ACOG) and Aquestive Therapeutics (NASDAQ:AQST) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings.

Alpha Cognition has a beta of 2.36, indicating that its stock price is 136% more volatile than the broader market. Comparatively, Aquestive Therapeutics has a beta of 1.46, indicating that its stock price is 46% more volatile than the broader market.

Alpha Cognition currently has a consensus price target of $14.67, indicating a potential upside of 148.17%. Aquestive Therapeutics has a consensus price target of $8.80, indicating a potential upside of 112.56%. Given Alpha Cognition's higher possible upside, research analysts plainly believe Alpha Cognition is more favorable than Aquestive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Alpha Cognition had 3 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 3 mentions for Alpha Cognition and 0 mentions for Aquestive Therapeutics. Aquestive Therapeutics' average media sentiment score of 1.89 beat Alpha Cognition's score of 1.06 indicating that Aquestive Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Alpha Cognition	Positive
Aquestive Therapeutics	Very Positive

Alpha Cognition has higher earnings, but lower revenue than Aquestive Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Alpha Cognition, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Cognition	$10.22M	12.59	-$20.67M	-$1.35	N/A
Aquestive Therapeutics	$44.54M	11.66	-$83.78M	-$0.61	N/A

32.5% of Aquestive Therapeutics shares are held by institutional investors. 14.0% of Alpha Cognition shares are held by company insiders. Comparatively, 6.8% of Aquestive Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Aquestive Therapeutics has a net margin of -137.08% compared to Alpha Cognition's net margin of -232.23%. Aquestive Therapeutics' return on equity of 0.00% beat Alpha Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Cognition	-232.23%	-58.35%	-45.99%
Aquestive Therapeutics	-137.08%	N/A	-49.33%

Summary

Alpha Cognition and Aquestive Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Alpha Cognition compare to Contineum Therapeutics?

Alpha Cognition (NASDAQ:ACOG) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

Alpha Cognition has higher earnings, but lower revenue than Contineum Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Alpha Cognition, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Cognition	$10.22M	12.59	-$20.67M	-$1.35	N/A
Contineum Therapeutics	$50M	9.23	-$59.98M	-$1.95	N/A

In the previous week, Alpha Cognition had 2 more articles in the media than Contineum Therapeutics. MarketBeat recorded 3 mentions for Alpha Cognition and 1 mentions for Contineum Therapeutics. Alpha Cognition's average media sentiment score of 1.06 beat Contineum Therapeutics' score of 0.93 indicating that Alpha Cognition is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alpha Cognition	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Contineum Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alpha Cognition currently has a consensus price target of $14.67, suggesting a potential upside of 148.17%. Contineum Therapeutics has a consensus price target of $20.00, suggesting a potential upside of 62.07%. Given Alpha Cognition's stronger consensus rating and higher possible upside, equities analysts clearly believe Alpha Cognition is more favorable than Contineum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Contineum Therapeutics has a net margin of 0.00% compared to Alpha Cognition's net margin of -232.23%. Contineum Therapeutics' return on equity of -27.09% beat Alpha Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Cognition	-232.23%	-58.35%	-45.99%
Contineum Therapeutics	N/A	-27.09%	-25.64%

Alpha Cognition has a beta of 2.36, indicating that its share price is 136% more volatile than the broader market. Comparatively, Contineum Therapeutics has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market.

Summary

Alpha Cognition beats Contineum Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Alpha Cognition compare to Coeptis Therapeutics?

Alpha Cognition (NASDAQ:ACOG) and Coeptis Therapeutics (NASDAQ:ZSQR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.

Coeptis Therapeutics has lower revenue, but higher earnings than Alpha Cognition. Alpha Cognition is trading at a lower price-to-earnings ratio than Coeptis Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Cognition	$10.22M	12.59	-$20.67M	-$1.35	N/A
Coeptis Therapeutics	N/A	N/A	-$11.92M	-$2.52	N/A

Alpha Cognition presently has a consensus price target of $14.67, suggesting a potential upside of 148.17%. Given Alpha Cognition's stronger consensus rating and higher possible upside, equities research analysts clearly believe Alpha Cognition is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

13.9% of Coeptis Therapeutics shares are held by institutional investors. 14.0% of Alpha Cognition shares are held by insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Alpha Cognition had 2 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 3 mentions for Alpha Cognition and 1 mentions for Coeptis Therapeutics. Alpha Cognition's average media sentiment score of 1.06 beat Coeptis Therapeutics' score of 0.94 indicating that Alpha Cognition is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alpha Cognition	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Coeptis Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alpha Cognition has a beta of 2.36, meaning that its share price is 136% more volatile than the broader market. Comparatively, Coeptis Therapeutics has a beta of -0.22, meaning that its share price is 122% less volatile than the broader market.

Alpha Cognition has a net margin of -232.23% compared to Coeptis Therapeutics' net margin of -810.04%. Alpha Cognition's return on equity of -58.35% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Cognition	-232.23%	-58.35%	-45.99%
Coeptis Therapeutics	-810.04%	-92.29%	-73.52%

Summary

Alpha Cognition beats Coeptis Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Alpha Cognition compare to Immix Biopharma?

Alpha Cognition (NASDAQ:ACOG) and Immix Biopharma (NASDAQ:IMMX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, dividends, valuation and earnings.

Alpha Cognition has higher revenue and earnings than Immix Biopharma. Immix Biopharma is trading at a lower price-to-earnings ratio than Alpha Cognition, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Cognition	$10.22M	12.59	-$20.67M	-$1.35	N/A
Immix Biopharma	N/A	N/A	-$29.44M	-$0.92	N/A

11.3% of Immix Biopharma shares are owned by institutional investors. 14.0% of Alpha Cognition shares are owned by insiders. Comparatively, 30.3% of Immix Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Alpha Cognition has a beta of 2.36, meaning that its share price is 136% more volatile than the broader market. Comparatively, Immix Biopharma has a beta of 0.1, meaning that its share price is 90% less volatile than the broader market.

Alpha Cognition presently has a consensus target price of $14.67, indicating a potential upside of 148.17%. Immix Biopharma has a consensus target price of $19.50, indicating a potential upside of 131.59%. Given Alpha Cognition's stronger consensus rating and higher probable upside, analysts clearly believe Alpha Cognition is more favorable than Immix Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Immix Biopharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Immix Biopharma has a net margin of 0.00% compared to Alpha Cognition's net margin of -232.23%. Alpha Cognition's return on equity of -58.35% beat Immix Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Cognition	-232.23%	-58.35%	-45.99%
Immix Biopharma	N/A	-73.24%	-59.20%

In the previous week, Alpha Cognition had 2 more articles in the media than Immix Biopharma. MarketBeat recorded 3 mentions for Alpha Cognition and 1 mentions for Immix Biopharma. Alpha Cognition's average media sentiment score of 1.06 beat Immix Biopharma's score of 0.93 indicating that Alpha Cognition is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alpha Cognition	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immix Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Alpha Cognition beats Immix Biopharma on 10 of the 15 factors compared between the two stocks.

How does Alpha Cognition compare to Sutro Biopharma?

Alpha Cognition (NASDAQ:ACOG) and Sutro Biopharma (NASDAQ:STRO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk, profitability and media sentiment.

Alpha Cognition has higher earnings, but lower revenue than Sutro Biopharma. Alpha Cognition is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Cognition	$10.22M	12.59	-$20.67M	-$1.35	N/A
Sutro Biopharma	$102.48M	4.64	-$191.09M	-$11.04	N/A

97.0% of Sutro Biopharma shares are owned by institutional investors. 14.0% of Alpha Cognition shares are owned by insiders. Comparatively, 3.6% of Sutro Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Sutro Biopharma has a net margin of -154.21% compared to Alpha Cognition's net margin of -232.23%. Sutro Biopharma's return on equity of 0.00% beat Alpha Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Cognition	-232.23%	-58.35%	-45.99%
Sutro Biopharma	-154.21%	N/A	-69.20%

In the previous week, Alpha Cognition had 1 more articles in the media than Sutro Biopharma. MarketBeat recorded 3 mentions for Alpha Cognition and 2 mentions for Sutro Biopharma. Alpha Cognition's average media sentiment score of 1.06 beat Sutro Biopharma's score of 0.72 indicating that Alpha Cognition is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alpha Cognition	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sutro Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alpha Cognition has a beta of 2.36, indicating that its share price is 136% more volatile than the broader market. Comparatively, Sutro Biopharma has a beta of 1.54, indicating that its share price is 54% more volatile than the broader market.

Alpha Cognition currently has a consensus target price of $14.67, indicating a potential upside of 148.17%. Sutro Biopharma has a consensus target price of $49.11, indicating a potential upside of 71.24%. Given Alpha Cognition's higher possible upside, research analysts plainly believe Alpha Cognition is more favorable than Sutro Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Sutro Biopharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	3 Strong Buy rating(s)	3.00

Summary

Alpha Cognition beats Sutro Biopharma on 9 of the 16 factors compared between the two stocks.

Get Alpha Cognition News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACOG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACOG vs. The Competition

Export

Metric	Alpha Cognition	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$128.66M	$3.34B	$6.44B	$12.46B
Dividend Yield	N/A	2.37%	2.69%	5.22%
P/E Ratio	-4.38	18.78	23.87	24.36
Price / Sales	12.59	320.80	521.52	117.06
Price / Cash	N/A	110.40	41.27	57.13
Price / Book	2.05	6.80	9.99	6.73
Net Income	-$20.67M	$24.09M	$3.56B	$337.03M
7 Day Performance	-0.51%	-2.56%	-0.90%	0.08%
1 Month Performance	N/A	N/A	N/A	-1.78%
1 Year Performance	-38.24%	48.90%	28.77%	33.98%

Alpha Cognition Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACOG Alpha Cognition	3.6025 of 5 stars	$5.91 -2.8%	$14.67 +148.2%	-37.9%	$128.66M	$10.22M	N/A	N/A
AQST Aquestive Therapeutics	3.2183 of 5 stars	$4.04 -1.1%	$8.80 +118.1%	+26.7%	$506.19M	$50.27M	N/A	160	Positive News
CTNM Contineum Therapeutics	3.5121 of 5 stars	$13.51 -1.4%	$20.00 +48.0%	+163.6%	$505.23M	N/A	N/A	31	Positive News
ZSQR Coeptis Therapeutics	0.4179 of 5 stars	$9.76 +3.1%	N/A	+12.1%	$501.96M	$1.36M	N/A	2	News Coverage High Trading Volume
IMMX Immix Biopharma	2.9034 of 5 stars	$8.98 +1.5%	$19.50 +117.3%	+300.0%	$487.35M	N/A	N/A	9	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACOG) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alpha Cognition (ACOG) Competitors

ACOG vs. AQST, CTNM, ZSQR, IMMX, and STRO

How does Alpha Cognition compare to Aquestive Therapeutics?

Summary

How does Alpha Cognition compare to Contineum Therapeutics?

Summary

How does Alpha Cognition compare to Coeptis Therapeutics?

Summary

How does Alpha Cognition compare to Immix Biopharma?

Summary

How does Alpha Cognition compare to Sutro Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACOG vs. The Competition

Alpha Cognition Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alpha Cognition (ACOG) Competitors

ACOG vs. AQST, CTNM, ZSQR, IMMX, and STRO

How does Alpha Cognition compare to Aquestive Therapeutics?

Which has more volatility and risk, ACOG or AQST?

Do analysts rate ACOG or AQST?

Does the media refer more to ACOG or AQST?

Which has better earnings and valuation, ACOG or AQST?

Do institutionals & insiders have more ownership in ACOG or AQST?

Is ACOG or AQST more profitable?

Summary

How does Alpha Cognition compare to Contineum Therapeutics?

Which has preferable valuation and earnings, ACOG or CTNM?

Does the media refer more to ACOG or CTNM?

Do analysts rate ACOG or CTNM?

Is ACOG or CTNM more profitable?

Which has more volatility and risk, ACOG or CTNM?

Summary

How does Alpha Cognition compare to Coeptis Therapeutics?

Which has preferable valuation & earnings, ACOG or ZSQR?

Do analysts rate ACOG or ZSQR?

Do insiders & institutionals hold more shares of ACOG or ZSQR?

Does the media prefer ACOG or ZSQR?

Which has more volatility & risk, ACOG or ZSQR?

Is ACOG or ZSQR more profitable?

Summary

How does Alpha Cognition compare to Immix Biopharma?

Which has higher earnings and valuation, ACOG or IMMX?

Do institutionals and insiders believe in ACOG or IMMX?

Which has more volatility and risk, ACOG or IMMX?

Do analysts prefer ACOG or IMMX?

Is ACOG or IMMX more profitable?

Does the media refer more to ACOG or IMMX?

Summary

How does Alpha Cognition compare to Sutro Biopharma?

Which has stronger earnings and valuation, ACOG or STRO?

Do insiders and institutionals have more ownership in ACOG or STRO?

Is ACOG or STRO more profitable?

Does the media refer more to ACOG or STRO?

Which has more risk & volatility, ACOG or STRO?

Do analysts prefer ACOG or STRO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACOG vs. The Competition

Alpha Cognition Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools